---
title: "RTXC: Net profit in 2025 is expected to increase by 118.67%-183.68% year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274125713.md"
description: "36Kr learned that RTXC released its performance forecast for 2025. The report shows that RTXC expects a net profit attributable to shareholders of the listed company to be between 185 million yuan and 240 million yuan in 2025, an increase of 118.67% to 183.68% compared to the same period last year"
datetime: "2026-01-29T09:29:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274125713.md)
  - [en](https://longbridge.com/en/news/274125713.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274125713.md)
---

# RTXC: Net profit in 2025 is expected to increase by 118.67%-183.68% year-on-year

36Kr learned that RTXC released its performance forecast for 2025. The report shows that RTXC expects a net profit attributable to shareholders of the listed company to be between 185 million yuan and 240 million yuan in 2025, an increase of 118.67% to 183.68% compared to the same period last year

### Related Stocks

- [301238.CN](https://longbridge.com/en/quote/301238.CN.md)

## Related News & Research

- [Soybeans Pushing Gains to Tuesday Morning](https://longbridge.com/en/news/286929660.md)
- [Korean robotics, AI firms interested in Việt Nam](https://longbridge.com/en/news/286636962.md)
- [PTA-DD: Warimpex Finanz- und Beteiligungs AG: Managers' transactions announcement according to article 19 MAR](https://longbridge.com/en/news/286901864.md)
- [Valhalla Metals Announces Closing of First Tranche of Over-Subscribed Private Placement | VMXXF Stock News](https://longbridge.com/en/news/286904505.md)
- [4basebio signs clinical supply agreement for Phase II immunotherapy trial opDNA material](https://longbridge.com/en/news/287052696.md)